Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Hong Kong Pharma Digital Technology Co. Ltd. (HKPD:NASDAQ), powered by AI.
Hong Kong Pharma Digital Technology Co. Ltd. is currently trading at $0.33. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Hong Kong Pharma Digital Technology Co. Ltd. on Alpha Lenz.
Hong Kong Pharma Digital Technology Co. Ltd.'s P/E ratio is -125.5.
“Hong Kong Pharma Digital Technology Co. Ltd. trades at a P/E of -125.5 (undervalued) with modest ROE of -0.6%.”
Ask for details →Hong Kong Pharma Digital Technology Co. Ltd. is a distinguished enterprise at the intersection of pharmaceutical innovation and digital technology. The company primarily focuses on leveraging advanced digital technologies to enhance pharmaceutical development and healthcare solutions. Its initiatives include integrating data analytics and software platforms to optimize drug discovery processes, improve patient care, and streamline healthcare management. As part of the broader pharmaceutical and healthcare sectors, Hong Kong Pharma Digital Technology plays a crucial role in bridging traditional medicine with cutting-edge technology, thereby driving efficiency and efficacy in healthcare delivery. In the context of market significance, the company's digital approach positions it as a transformative player in the industry, appealing to investors interested in the convergence of technology and healthcare. This integration supports innovation and adaptation in rapidly evolving global health landscapes, underscoring the firm’s potential impact on both local and international scales.
“Hong Kong Pharma Digital Technology Co. Ltd. trades at a P/E of -125.5 (undervalued) with modest ROE of -0.6%.”
Ask for details →Hong Kong Pharma Digital Technology Co. Ltd. (ticker: HKPD) is a company listed on NASDAQ in the Healthcare sector (Pharmaceutical Retailers). It has approximately 27 employees. Market cap is $3M.
The current price is $0.333 with a P/E ratio of -125.46x and P/B of 0.68x.
ROE is -0.59% and operating margin is 0.99%. Annual revenue is $20M.